Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Neuraltus Pharmaceuticals
San Bruno, California, United Statesneuraltus.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
Neuraltus’ lead candidate, NP001, was a novel small molecule immune regulator targeting inflammation in ALS. Initial Phase II data suggested possible benefit in patients with elevated systemic inflammation biomarkers, but a larger confirmatory Phase IIb trial failed to meet primary and secondary endpoints. The company ceased operations following this failure.[5][6]
- Therapeutic areas
- OncologyImmunologyRare DiseasesNeurology
- Modalities
- Small moleculesImmune regulators
- Industry
- Biotech
02
Partnerships
Collaborated with global ALS specialists and patient advocacy organizations during development; no major pharma partnerships disclosed.[2]
Beyond the preview
Go deeper on Neuraltus Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuraltus Pharmaceuticals.